Detection of Ultrasound Contrast Signals in the Cerebral Circulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00579241
Recruitment Status : Withdrawn
First Posted : December 24, 2007
Last Update Posted : July 23, 2012
Information provided by (Responsible Party):
Thomas R. Porter, MD, University of Nebraska

Brief Summary:
To Determine whether transcranial ultrasound can detect the presence of intravenously injected microbubbles used routinely for dobutamine stress echocardiography.

Condition or disease Intervention/treatment Phase
Brain Vascular Disorders Coronary Artery Disease Procedure: Ultrasound on Temporal Bone Not Applicable

Detailed Description:
The purpose of this study is to determine whether the intravenous microbubbles used to improve border delineation during dobutamine stress echocardiographies (DSE) can be detected within the cerebral circulation.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Detection of Ultrasound Contrast Signals in the Cerebral Circulation During Stress Echocardiography
Study Start Date : April 2006
Actual Primary Completion Date : March 2010
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Transcranial imaging using Doppler ultrasound
Procedure: Ultrasound on Temporal Bone
All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.

Primary Outcome Measures :
  1. Detect abnormalities in cerebral blood flow [ Time Frame: immediate ]

Secondary Outcome Measures :
  1. if cerebral vascular disease is detected it would lead to further testing that may better identify abnormalities. [ Time Frame: within 30 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • male or female age >19 years of age
  • scheduled for a stress echocardiogram
  • negative urine pregnancy test within two hours of ultrasound contrast administration required for females of childbearing age unless post-menopausal or with evidence of surgical sterilization
  • be conscious and coherent, and able to communicate effectively with trial personnel

Exclusion Criteria:

  • pregnant or lactation
  • life expectancy of less than 2 months or terminally ill
  • Known or suspected hypersensitivity to ultrasound contrast agent used for the study
  • complicated hemodynamic instability
  • Known left main disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00579241

United States, Nebraska
University of Nebraska Medicial Center
Omaha, Nebraska, United States, 68105
Sponsors and Collaborators
University of Nebraska
Principal Investigator: Thomas R Porter, MD University of Nebraska Medicial Center

Responsible Party: Thomas R. Porter, MD, Professor, University of Nebraska Identifier: NCT00579241     History of Changes
Other Study ID Numbers: 113-06-FB
First Posted: December 24, 2007    Key Record Dates
Last Update Posted: July 23, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Vascular Diseases
Cerebrovascular Disorders
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases